Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)
- Conditions
- Ocular InflammationOcular Prostheses
- Interventions
- Registration Number
- NCT05668455
- Lead Sponsor
- Agnes
- Brief Summary
We propose to evaluate the efficacy of treatment with Hydrocortisone and Dexamethasone (in a cross-over design) in patients with ocular prostheses and significant functional discomfort.
- Detailed Description
There are more than 100,000 eye prosthesis wearers in France. Half of these patients are bothered by secretions or sandy sensations, or even chronic pain. Various anti-inflammatory treatments are proposed without scientific basis.
A pilot study on a limited number of patients conducted in 2017 at the University Hospital of Rennes and published in 2019 showed the interest of Dexamethasone eye drops in these patients. However, this study was retrospective and not controlled.
We therefore wish to propose a prospective, placebo-controlled, single-blind clinical study to define the value of anti-inflammatory treatment in patients with ocular prostheses.
We propose to evaluate the efficacy of treatment with Hydrocortisone and Dexamethasone (in a cross-over design) in patients with ocular prostheses and significant functional discomfort.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
- Patient aged 18 years or older;
- Wearing a permanent prosthesis for more than 6 months; - Consultant in the ophthalmology department;
- Modified OSDI score ≥ 20 points out of 40 ;
- Affiliated with a health insurance scheme,
- For women of childbearing age: effective contraception (effective contraception includes oral contraception, intrauterine devices and other forms of contraception with a failure rate <1%, for the duration of the study and up to 1 week after the last dose administered)
- Have given free, informed and written consent.
- Treatment with eye drop(s) (other than artificial tears or antiseptic) < 1 month;
- Concomitant treatment with CYP3A inhibitors including cobicistat containing drugs,
- Known contraindications to study treatments
- Dermal fat grafting or complicated cavity;
- Gougerot-Sjögren syndrome;
- Allergic conjunctivitis;
- Damaged prosthesis;
- Impossibility of carrying out the various tests required by the protocol for whatever reason (comprehension problems, motor disability);
- Pregnant or breastfeeding woman;
- Person already included in a RIPH1 research protocol with topical treatment of the cavity or systemic anti-inflammatory treatment and/or who could lead to a bias in the present study
- Person under legal protection (safeguard of justice, curatorship, guardianship) or person deprived of liberty.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description POVIDONE Povidone Topical : tear substitute DEXAMETHASONE Dexamethasone Topical corticosteroid : dexamethasone HYDROCORTISONE Hydrocortisone Topical corticosteroid : hydrocortisone
- Primary Outcome Measures
Name Time Method Secretion Self-Rating Analog Scale score. At 3.5 months (After third treatment period of 14 days) The overall score is analysed as the primary endpoint. Each sub-score is analysed independently in the secondary endpoints.
This 40-point score is calculated as the sum of 4 criteria, each scored on 10 points.
Analog scale from 1 to 10 on the frequency of secretions (from never to all the time) Analog scale from 1 to 10 on the colour of secretions (from clear to yellow) Analog scale from 1 to 10 on the quantity of secretions (from minimal to profuse) Analog scale from 1 to 10 on the viscosity of secretions (from liquid to very thick)
- Secondary Outcome Measures
Name Time Method Bulbar conjunctival inflammation score At 3.5 months (After third treatment period of 14 days) Bulbar conjunctival inflammation score according to the grades of Saini et al. (Grade 1 to 3 : from normal to severe)
Colour of secretions At 3.5 months (After third treatment period of 14 days) Analog scale from 1 to 10 on the colour of secretions (from clear to yellow) according to the secretion analysis scale (Jacobs et al.)
Tarsal conjunctival inflammation score according At 3.5 months (After third treatment period of 14 days) Tarsal conjunctival inflammation score according to the grades of Saini et al.(Grade 1 to 4 : from absent to more than one millimetre in diameter)
Secretion frequency At 3.5 months (After third treatment period of 14 days) Analog scale from 1 to 10 on the frequency of secretions (from never to all the time) according to the secretion analysis scale (Jacobs et al.)
Amount of secretions At 3.5 months (After third treatment period of 14 days) Analog scale from 1 to 10 on the quantity of secretions (from minimal to profuse) according to the secretion analysis scale (Jacobs et al.)
Thickness/Viscosity of secretions At 3.5 months (After third treatment period of 14 days) Analog scale from 1 to 10 on the viscosity of secretions (from liquid to very thick) to the secretion analysis scale (Jacobs et al.)
OSDI quality of life score adapted to prosthesis wearers At 3.5 months (After third treatment period of 14 days) OSDI quality of life score adapted to prosthesis wearers, scored on 40 points (10 items with a maximum of 4 points per item) (Maucourant et al.)
Trial Locations
- Locations (1)
Centre Hospitalier Universitaire de Rennes _ Pontchaillou
🇫🇷Rennes, France